Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2023 at "United European Gastroenterology Journal"
DOI: 10.1002/ueg2.12366
Abstract: Abstract Background and Aims The availability of biological agents for inflammatory bowel disease has increased over the past years. In this systematic review and meta‐analysis, we aimed to explore time trends in clinical response and… read more here.
Keywords: clinical remission; clinical response; remission; systematic review ... See more keywords
Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up
Sign Up to like & getrecommendations! Published in 2017 at "Rheumatology International"
DOI: 10.1007/s00296-017-3757-7
Abstract: The current strategy for managing rheumatoid arthritis (RA) focuses on achieving clinical remission. Once remission is achieved and sustained over time, the most efficient strategy is dose optimization. This work describes the results of dose… read more here.
Keywords: years follow; remission; create registry; optimization ... See more keywords
Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials
Sign Up to like & getrecommendations! Published in 2020 at "EClinicalMedicine"
DOI: 10.1016/j.eclinm.2020.100271
Abstract: Background The therapeutic role of methotrexate (MTX) for management of inflammatory bowel disease (IBD) remains unclear. Methods We systematically reviewed randomized, controlled trials (RCTs) of MTX for induction and maintenance of remission in IBD until… read more here.
Keywords: maintenance; remission; disease; clinical remission ... See more keywords
Validation of a four items version of the Functional Remission of General Schizophrenia scale (the mini-FROGS) to capture the functional benefits of clinical remission
Sign Up to like & getrecommendations! Published in 2018 at "European Psychiatry"
DOI: 10.1016/j.eurpsy.2017.09.001
Abstract: Abstract Objectives We previously developed the Functional Remission Of General Schizophrenia (FROGS) scale demonstrating first, reliable assessment in a cross-sectional study and second, good time-stability. The purpose of the present analysis was to propose a… read more here.
Keywords: functional remission; schizophrenia; remission; clinical remission ... See more keywords
Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in arthritis and rheumatism"
DOI: 10.1016/j.semarthrit.2017.04.008
Abstract: OBJECTIVE The aim of the study is to assess the factors associated with clinical remission of patients with rheumatoid arthritis (RA) in daily clinical practice. METHODS This analysis was based on the data of 304… read more here.
Keywords: age; disease activity; remission; clinical remission ... See more keywords
Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn’s disease complicated with inflammatory mass
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-04984-z
Abstract: The ancient Chinese medical literature, as well as our prior clinical experience, suggests that fecal microbiota transplantation (FMT) could treat the inflammatory mass. We aimed to evaluate the efficacy and safety of multiple fresh FMTs… read more here.
Keywords: fmt; remission; inflammatory mass; clinical remission ... See more keywords
High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-05208-9
Abstract: The interleukin-6 family cytokine, oncostatin-M (OSM) has been associated with response to tumor necrosis factor-α antagonists (anti-TNFs) in small cohorts of patients with inflammatory bowel disease (IBD). We aimed to evaluate the association between plasma… read more here.
Keywords: anti tnf; clinical remission; tumor necrosis; disease ... See more keywords
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2095668
Abstract: Abstract Introduction There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. Methods We retrieved the full datasets of two observational, multicentre,… read more here.
Keywords: vedolizumab; ulcerative colitis; clinical remission; vedolizumab ustekinumab ... See more keywords
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2023.2185510
Abstract: ABSTRACT Background Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn’s disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ. Research design and methods Mayo… read more here.
Keywords: clinical remission; vedolizumab; crohn disease; ulcerative colitis ... See more keywords
OP25 Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab075.024
Abstract: Patients with ulcerative colitis (UC) often do not respond to treatment or lose response over time, and thus switch between therapies with various mechanisms of action (MoAs).1 Filgotinib (FIL) is a once-daily, oral, Janus kinase… read more here.
Keywords: fil 200; bio experienced; week; experienced patients ... See more keywords
OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab075.025
Abstract: Present therapies leave an unmet need for early and effective treatment for patients with Crohn’s disease (CD). Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody against the p19 subunit of interleukin-23, was evaluated as an… read more here.
Keywords: response; rzb; motivate; patients moderate ... See more keywords